Home
HK inno-n

HK inno-n Market Share Analysis for April 2026

바이오헬스기업 HK이노엔. 케이캡, 컨디션, 비원츠 등 전문의약품 및 헬스, 뷰티, 음료 제품 소개, 연구소개, ESG 등 정보 제공

Health > Medicine

Domaininno-n.com

Year Founded1984

Employees1001 - 5000

Annual Revenue--

HK inno-n

HK inno-n (including company regionals)

inno-n.com

See more website traffic and engagement information

Total visits to HK inno-n's top domains

Understand HK inno-n market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

inno-n.com130.3K

See more with Sales Intelligence

Avg. visit duration in HK inno-n's top domains

Analyze HK inno-n engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

inno-n.com00:03:34

See more with Sales Intelligence

Avg. pageviews on HK inno-n's top domains

See how HK inno-n keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

inno-n.com4.92

See more with Sales Intelligence

HK inno-n top competitors by domain

Top similar sites in April 2026, ranked by their affinity

roche.co.krCompany NameRocheEmployees> 10001HQSwitzerlandAnnual revenue> $1BTotal visits6.8KHealth > Biotechnology and Pharmaceuticals

Top technologies used by HK inno-n

These are the website technologies, by industry, used by HK inno-n top domains

Advertising (2)

DoubleClick

Mobile (2)

Meta Viewport

Social (2)

Instagram

Audio Video Media (1)

YouTube

More Technologies

5

See all

News & Signals from HK inno-n

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHK inno.N Corp. partnered with Atomatrix on Apr 27th '26.On April 27, HK inno.N announced that it has signed a joint research and development agreement with Atomatrix for the development of next-generation obesity treatments.

NewsHK inno.N Corp. attended event 9th Korea Digestive Disease Week on Jan 1st '25.HK inno.N announced on the 27th that Dr. Felice Schnoll-Sussman, the lead investigator of the U.S. Phase 3 clinical trials for its gastroesophageal reflux disease (GERD) treatment, K-CAB (active ingredient: tegoprazan), was invited to speak at the 9th Korea Digestive Disease Week (KDDW 2025).